ECSP024392A - GLUCAGON TYPE-1 PEPTIDE ANALOGS - Google Patents

GLUCAGON TYPE-1 PEPTIDE ANALOGS

Info

Publication number
ECSP024392A
ECSP024392A ECSP024392A ECSP024392A EC SP024392 A ECSP024392 A EC SP024392A EC SP024392 A ECSP024392 A EC SP024392A EC SP024392 A ECSP024392 A EC SP024392A
Authority
EC
Ecuador
Prior art keywords
glp
glu
asp
ala
lys
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Wolfgang Glaesner
Rohn Lee Millican Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP024392A publication Critical patent/ECSP024392A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto GLP-1 que comprende la secuencia de aminoácidos de fórmula 1 (SEQ ID No. 1) His-Xaa8-Glu-Gly-Xaa11-Xaa12-Thr-Ser-asp-Xaa16-Ser-Ser-Tyr-Leu-Glu-Xaa22-Xaa23-Xaa24-Ala-Xaa27-Phe-Ile-Ala-Xaa31-Leu-Xaa33-Xaa34-Xaa35-Xaa36-R . Fórmula I (SEQ ID No:1) en la que: Xaa8 es: Gly, Ala, Val, Leu, Ile, Ser o Thr; Xaa11 es: Asp, Glu, Arg, Thr, Ala, Lys o His; Xaa12 es: His, Trp, Phe o Tyr; Xaa16 es: Leu, Ser, Thr, Trp, His, Phe, Asp, Val, Tyr, Glu, o Ala; Xaa22 es: Gly, Asp, Glu, Gln, Asn, Lys, Arg, Cys o ácido cisteico; Xaa23 es: His, Asp, Lys, Glu, Gln o Arg; Xaa24 es: Glu, Arg, Ala o Lys; Xaa26 es; Trp, Tyr, Phe, Asp, Lys, Glu o His; Xaa27 es: Ala, Glu, His, Phe, Tyr, Trp, Arg o Lys; Xaa30 es: Ala, Glu, Asp, Ser o His; Xaa33 es: Asp, Arg, Val, Lys, Ala, Gly o Glu; Xaa34 es: Glu, Lys o Asp; Xaa35 es: Tbr, Ser, Lys, Arg, Trp, Tyr, Phe, Asp, Gly, Pro, His o Glu; Xaa36 es: Tbr, Ser, Asp, Trp, Tyr, Phe, Arg, Glu o His; R es: Lys, Arg, Tbr, Ser, Glu, Asp, Txp, Tyr, Phe, His, - NH2, Gly, Gly-Pro o Gly-Pro-Nh2 o no aparece. con la condición de que el compuesto GLP-1 no tenga la secuencia de GLP-1 (7-37) OH o GLP-1 (7-36) NH2 y, con tal de que el compuesto GLP-1 no sea Gly8-GLP.-1(7-37)OH, Gly8-GLP-1(7-36)NH2, Val8-GLP1-(7-37)OHM Leu8-GLP-1(7-36)NH2, Ile8-GLP-1(7-37)OH, Ile8-GLP-1(7-36NH2, Ser8- GLP-1(7-37)OH,Ser8-GLP1(7-36)NH2, Thr8-GLP-1(7-37)OH,o Thr8-GLP-1-(7-36)nh2, aLA11-glp-1(7-37)oh, aLA11-glp-1(7-36)NH2, Ala 16-GLP-1(7-37) OH, Ala16-GLP-1(7-36)NH2M ALA18-GLP-1(7-37)OH, Ala 18-GLP-1(7-36)NH2, Ala 27-GLP-1/7-37)OH, Ala27,-GLP-1(7-36)NH2, Ala33-GLP-(7-37) OH, Ala33-GLP-1(7-36NH2.A GLP-1 compound comprising the amino acid sequence of formula 1 (SEQ ID No. 1) His-Xaa8-Glu-Gly-Xaa11-Xaa12-Thr-Ser-asp-Xaa16-Ser-Ser-Tyr-Leu-Glu -Xaa22-Xaa23-Xaa24-Ala-Xaa27-Phe-Ile-Ala-Xaa31-Leu-Xaa33-Xaa34-Xaa35-Xaa36-R. Formula I (SEQ ID No: 1) in which: Xaa8 is: Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa11 is: Asp, Glu, Arg, Thr, Ala, Lys or His; Xaa12 is: His, Trp, Phe or Tyr; Xaa16 is: Leu, Ser, Thr, Trp, His, Phe, Asp, Val, Tyr, Glu, or Ala; Xaa22 is: Gly, Asp, Glu, Gln, Asn, Lys, Arg, Cys or cysteic acid; Xaa23 is: His, Asp, Lys, Glu, Gln or Arg; Xaa24 is: Glu, Arg, Ala or Lys; Xaa26 is; Trp, Tyr, Phe, Asp, Lys, Glu or His; Xaa27 is: Ala, Glu, His, Phe, Tyr, Trp, Arg or Lys; Xaa30 is: Ala, Glu, Asp, Ser or His; Xaa33 is: Asp, Arg, Val, Lys, Ala, Gly or Glu; Xaa34 is: Glu, Lys or Asp; Xaa35 is: Tbr, Ser, Lys, Arg, Trp, Tyr, Phe, Asp, Gly, Pro, His or Glu; Xaa36 is: Tbr, Ser, Asp, Trp, Tyr, Phe, Arg, Glu or His; R is: Lys, Arg, Tbr, Ser, Glu, Asp, Txp, Tyr, Phe, His, - NH2, Gly, Gly-Pro or Gly-Pro-Nh2 or does not appear. with the proviso that the GLP-1 compound does not have the sequence of GLP-1 (7-37) OH or GLP-1 (7-36) NH2 and, provided that the GLP-1 compound is not Gly8-GLP .-1 (7-37) OH, Gly8-GLP-1 (7-36) NH2, Val8-GLP1- (7-37) OHM Leu8-GLP-1 (7-36) NH2, Ile8-GLP-1 ( 7-37) OH, Ile8-GLP-1 (7-36NH2, Ser8-GLP-1 (7-37) OH, Ser8-GLP1 (7-36) NH2, Thr8-GLP-1 (7-37) OH, or Thr8-GLP-1- (7-36) nh2, aLA11-glp-1 (7-37) oh, aLA11-glp-1 (7-36) NH2, Ala 16-GLP-1 (7-37) OH , Ala16-GLP-1 (7-36) NH2M ALA18-GLP-1 (7-37) OH, Ala 18-GLP-1 (7-36) NH2, Ala 27-GLP-1 / 7-37) OH, Ala27, -GLP-1 (7-36) NH2, Ala33-GLP- (7-37) OH, Ala33-GLP-1 (7-36NH2.

ECSP024392 2000-06-16 2002-12-13 GLUCAGON TYPE-1 PEPTIDE ANALOGS ECSP024392A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21217100P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
ECSP024392A true ECSP024392A (en) 2003-02-06

Family

ID=32849305

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP024392 ECSP024392A (en) 2000-06-16 2002-12-13 GLUCAGON TYPE-1 PEPTIDE ANALOGS

Country Status (3)

Country Link
EC (1) ECSP024392A (en)
UA (1) UA88862C2 (en)
ZA (1) ZA200210098B (en)

Also Published As

Publication number Publication date
ZA200210098B (en) 2004-03-12
UA88862C2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
AR031701A1 (en) COMPOUNDS ANA LOGOS OF (GLP-1) -PEPTIDE-1 GLUCAGON ANALOG, METHOD FOR STIMULATING GLP-1 RECEPTORS USING SUCH COMPOUNDS AND USING SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES TO STIMULATE THE INSULIN SECRETION
AR038102A1 (en) GLUCAGON TYPE 1 PEPTIDE EXTENDED ANALOGS
JP2008500281A5 (en)
JP2019504057A5 (en)
CA2320371A1 (en) Inotropic and diuretic effects of exendin and glp-1
CA2277112C (en) Use of exendins and agonists thereof for the reduction of food intake
CA2309356A1 (en) Novel exendin agonist compounds
RU2009126634A (en) Peptide pharmaceutical compositions and drugs on its base, method of treatment and / or prevention of diabetes or a condition associated with obesity, a method of reducing appetite, reduced food intake, a decrease in caloric intake, a decrease in body weight and increase in costs ENERGY
CA2310097A1 (en) Novel exendin agonist compounds
ES2614603T3 (en) GLP-1 Molecule Administration Procedure
US1315215A (en) Rifle-stock.
CL2021000158A1 (en) Gip / glp1 coagonist compounds
JP2009529553A5 (en)
WO2019085772A1 (en) Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide
CA2299425A1 (en) Novel exendin agonist compounds
CA2048910A1 (en) Antimicrobial peptides active against plant pathogens, their method of use and various screening methods pertaining thereto
W. POTTS et al. The effects of hypophysectomy and bovine prolactin on salt fluxes in fresh-water-adapted Fundulus heteroclitus
PE20230861A1 (en) LONG-ACTING GLP-1/GIP DOUBLE AGONISTS
ECSP024392A (en) GLUCAGON TYPE-1 PEPTIDE ANALOGS
AR047776A1 (en) GLP PHARMACEUTICAL COMPOSITIONS - 1
CO2020012425A2 (en) Novel analogs of glp-1
UA102370C2 (en) Peptide, pharmaceutical composition and medicament comprising thereof, method for the treatment and/or prevention of diabetes and diseases associated with obesity, method for reduction in appetite, reduction in food intake or reduction of calorie intake
ATE332921T1 (en) NEW PEPTIDE COMPOSITIONS AND THE USE THEREOF, IN PARTICULAR FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS ACTIVE AGAINST THE HEPATITIS C VIRUS
Holst Glucagon-like peptide-1: physiology and therapeutic potential
US3628519A (en) Demountable archery bow